Menu
Search
|

Menu

Close
X

Jaguar Health Inc JAGX.OQ (NASDAQ Stock Exchange Capital Market)

0.43 USD
+0.00 (+0.00%)
As of Nov 19
chart
Previous Close 0.43
Open 0.44
Volume 31,631
3m Avg Volume 295,622
Today’s High 0.44
Today’s Low 0.42
52 Week High 6.60
52 Week Low 0.40
Shares Outstanding (mil) 67.70
Market Capitalization (mil) 14.22
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
4
FY16
0
FY15
0
EPS (USD)
FY18
-1.293
FY17
-9.182
FY16
-20.561
FY15
-35.459
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
7.91
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
--
15.71
LT Debt to Equity (MRQ)
vs sector
--
11.53
Return on Investment (TTM)
vs sector
--
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

James Bochnowski
Chairman of the Board, Since 2014
Salary: --
Bonus: --
Lisa Conte
President, Chief Executive Officer, Director, Since 2013
Salary: --
Bonus: --
Karen Wright
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Steven King
Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary, Since 2014
Salary: --
Bonus: --
Roger Waltzman
Executive Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

201 Mission St Ste 2375
SAN FRANCISCO   CA   94105-1839

Phone: +1415.8965081

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

SPONSORED STORIES